相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
Vita Golubovskaya et al.
CANCERS (2021)
CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus
Ana Textor et al.
CANCERS (2021)
Multiple myeloma: the (r)evolution of current therapy and a glance into the future
Annamaria Gulla et al.
HAEMATOLOGICA (2020)
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Luis Gerardo Rodriguez-Lobato et al.
FRONTIERS IN ONCOLOGY (2020)
Multiple myeloma: Every year a new standard?
S. Vincent Rajkumar
HEMATOLOGICAL ONCOLOGY (2019)
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Ru Zhou et al.
FRONTIERS IN IMMUNOLOGY (2019)
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
Daniel Feinberg et al.
CELLULAR IMMUNOLOGY (2019)
Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform
Julian Rydzek et al.
MOLECULAR THERAPY (2019)
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
William R. Strohl et al.
ANTIBODIES (2019)
Emerging immune targets for the treatment of multiple myeloma
Atif Sohail et al.
IMMUNOTHERAPY (2018)
Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
Wolfgang Willenbacher et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Nicla Porciello et al.
NATURE COMMUNICATIONS (2018)
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
Ciprian Tomuleasa et al.
FRONTIERS IN IMMUNOLOGY (2018)
CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
Robert Berahovich et al.
CANCERS (2018)
Disease Milestones through Bibliometric Analysis of the Top 100 Cited Articles in Multiple Myeloma
Azka Latif et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2018)
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Gongbo Li et al.
JCI INSIGHT (2018)
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
D. Sommermeyer et al.
LEUKEMIA (2017)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
Treatment of relapsed and refractory multiple myeloma
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
Treatment of relapsed and refractory multiple myeloma
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
Salma Afifi et al.
PHARMACOTHERAPY (2015)
Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis
Tengfei Zhang et al.
ONCOTARGET (2015)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma
Esther Drent et al.
BLOOD (2014)
Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28 OX40 Super-stimulation
Andreas A. Hombach et al.
MOLECULAR THERAPY (2013)
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
K. Mihara et al.
LEUKEMIA (2012)
Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
Evripidis Lanitis et al.
MOLECULAR THERAPY (2012)
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1
J. Bhattacharyya et al.
BLOOD CANCER JOURNAL (2012)
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
Cor H. J. Lamers et al.
BLOOD (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Activated T-cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma
Keichiro Mihara et al.
JOURNAL OF IMMUNOTHERAPY (2009)
分享论文
